Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | BACE1 | P56817 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CD4 | P01730 | 2/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952496 | 1.00 | HTR6 (0.53) | HTR6CYP2D6BCHEACHEBACE1 | |
| SCHEMBL952495 | 1.00 | HTR6 (0.53) | HTR6CYP2D6BCHEACHEBACE1 | |
| SCHEMBL5743312 | 0.93 | BCHE (0.52) | HTR6CYP2D6BCHESMN1; SMN2ALDH1A1 | |
| SCHEMBL28508903 | 0.93 | BCHE (0.52) | HTR6CYP2D6BCHESMN1; SMN2ALDH1A1 | |
| SCHEMBL5744572 | 0.93 | CYP2D6 (0.57) | HTR6CYP2D6ACHEBACE1SMN1; SMN2 | |
| SCHEMBL5746064 | 0.90 | LMNA (0.49) | HTR6CYP2D6BCHEACHEBACE1 | |
| SCHEMBL5743822 | 0.85 | HTR6 (0.50) | HTR6CYP2D6BCHEACHEBACE1 | |
| SCHEMBL5743236 | 0.85 | HTR6 (0.50) | HTR6CYP2D6BCHEACHEBACE1 | |
| SCHEMBL3386992 | 0.83 | CYP2D6 (0.58) | CYP2D6LMNAPOLBALDH1A1CYP1A2 | |
| SCHEMBL14891143 | 0.83 | CYP2D6 (0.58) | CYP2D6LMNAPOLBALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| WO-2010133544-A1 | PIPERAZINE AND AMINOPYRROLIDINE COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2010-11-25 | — | — | WO | disclosed |
| US-7728131-B2 | 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia | NIPPON SHINYAKU CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
| EP-0900787-B1 | PROCESS FOR PREPARING PYRROLIDINE DERIVATIVES | KANEKA CORP (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-6005119-A | Process for preparing pyrrolidine derivatives | KANEKA CORPORATION (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0900787-A1 | PROCESS FOR PREPARING PYRROLIDINE DERIVATIVES | KANEKA CORPORATION (JP) | 1999-03-10 | — | — | EP | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293940-A1 | Amide Derivative and Medicine | ABL2, ABL1, BCR | HTR6 1321/4885CYP2D6 436/4885BCHE 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.